DocDoc to work with Aon and insurers in Asia to offer data-enabled patient empowerment solutions to members of employer health plans
This collaboration will address a growing need among employers for effective cost-containment solutions, which empower their members with the data they need to make impactful healthcare decisions. DocDoc's data-enabled group health insurance solutions are to be offered to Aon's clients across multiple markets in Asia starting with Singapore in October 2022, followed by other markets in the region, in...
Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders
SANTA CLARA, Calif., Nov. 8, 2022 /PRNewswire/ -- Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Under the terms of the agreement, Cyagen will apply its proprietary artificial intelligence (AI)-powered high-throughput platform to discover novel AAV vectors with optimized tissue targeting...
Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment
Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the Company has dosed the first patient in a Phase I clinical study of STP705, a siRNA (small...
Sophie’s BioNutrients Debuts Chlorella Ice Cream to Storm the Vegan Ice Cream Industry
Sophie's BioNutrients introduces sustainable and nutritious ice cream with double the action for the sweet tooth. WAGENINGEN, Netherlands, Nov. 7, 2022 /PRNewswire/ -- Sophie's BioNutrients, a next-generation sustainable urban food production technology company, together with Danish Technological Institute (DTI), a green solutions facilitator in Denmark, collaborated to produce its first chlorella-based ice cream,...
Alterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
MELBOURNE, Australia and SAN FRANCISCO, Nov. 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced a poster presentation from the ongoing Biomarkers of Progression in Multiple System Atrophy (bioMUSE) natural history study was given at...
National Institute of Korean Medicine shows a new trend in Korean Medicine in Times Square, New York
Korean wave towards K-medicine, from K-food, K-pop and K-movies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The National Development Institute of Korean Medicine (NIKOM) said a promotional video showing the value of Korean Medicine will be played on the electronic display of the Nasdaq building in Times Square, New York on November 11. Promotional video showing the...
Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research–Findings to be Presented at SITC 2022
Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- Lunit (KRX: 328130.KQ) today announced that it...
SeekIn Demonstrates the Power of Treatment Response Monitoring Test at the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo
SeekInClarity is a CE-IVD Mark, cost-effective, blood-based pan-cancer/pan-indication treatment response monitoring test that does not require cancer tissue analysis. SeekInClarity test could identify a subgroup of patients as responders, who have better survival regardless of disease subtypes and stages, after the first or second cycles of treatment. SHENZHEN, China, Nov. 7, 2022 /PRNewswire/ -- SeekIn Inc, a...
Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting
VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies HMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination with...
Ainos Reports Unaudited Third Quarter 2022 Financial Results
Revenues increased by 384% year over year Debt ratio decreased to 7% from 75% at year-end 2021 SAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its unaudited financial...
